Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

Author(s):
Groot, S. de; Charehbili, A.; Laarhoven, H.W.M. van; Mooyaart, A.L.; Dekker-Ensink, N.G.; Ven, S. van de; Janssen, L.G.M.; Swen, J.J.; Smit, V.T.H.B.M.; Heijns, J.B.; Kessels, L.W.; Straaten, T. van der; Bohringer, S.; Gelderblom, H.; Hoeven, J.J.M. van der; Guchelaar, H.J. (0000-0002-7085-1383); Pijl, H. (0000-0002-3076-1551); Kroep, J.R.; Dutch Breast Canc Res Grp
Published
2016
Publication type
Article / Letter to editor
Breast cancerNeoadjuvant chemotherapyGlucoseInsulinIGF-1IGF-BP3IGF-1RMiller and PaynePathological complete responseSingle nucleotide polymorphisms
Date issued
2016-01-06
Language
English
Is part of
Breast Cancer Research
hdl
1887/113129
doi
10.1186/s13058-015-0663-3